Investigating how CDK6 affects T-cell leukemia progression
Novel functions of CDK6 in T-cell leukemia progression
This study is looking at a protein called CDK6 to see if blocking it can help stop the spread of T-cell leukemia, which could lead to better treatments for patients dealing with this type of cancer.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Medical University of South Carolina NIH-funded |
| Lab location | 1 site (Charleston, United States) |
| Project ID | NIH-10896985 on NIH RePORTER |
What this research studies
This research focuses on understanding the role of CDK6, a protein involved in cell cycle regulation, in the progression of T-cell leukemia. The study aims to explore how inhibiting CDK6 can prevent the spread of malignant T-cells, which is a major cause of treatment failure. Researchers will investigate the mechanisms by which CDK6 influences the movement and survival of these cancer cells, particularly through its effects on other proteins involved in cell growth and apoptosis. By conducting laboratory experiments and translational studies, the research seeks to provide insights that could lead to new therapeutic strategies for patients with T-cell leukemia.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with T-cell leukemia, particularly those whose disease has not responded well to existing treatments.
Not a fit: Patients with other types of leukemia or those who do not have T-cell leukemia may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for T-cell leukemia, potentially improving survival rates and quality of life for patients.
How similar studies have performed: Previous research has shown promising results in targeting CDK6 for cancer treatment, indicating that this approach may be effective for T-cell leukemia as well.
Where this research is happening
Charleston, United States
- Medical University of South Carolina — Charleston, United States (Active)
Researchers
- Principal investigator: Wang, Haizhen — Medical University of South Carolina
- Study coordinator: Wang, Haizhen
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.